KUČEROVÁ, Jana, Zuzana BABINSKÁ, Kateřina HORSKÁ and Hana KOTOLOVA. The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review. Biomedical Papers. Olomouc: Palacký University, 2015, vol. 159, No 2, p. 208-214. ISSN 1213-8118. Available from: https://dx.doi.org/10.5507/bp.2014.060.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review
Authors KUČEROVÁ, Jana (203 Czech Republic, guarantor, belonging to the institution), Zuzana BABINSKÁ (703 Slovakia, belonging to the institution), Kateřina HORSKÁ (203 Czech Republic) and Hana KOTOLOVA (203 Czech Republic).
Edition Biomedical Papers, Olomouc, Palacký University, 2015, 1213-8118.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 0.924
RIV identification code RIV/00216224:14110/15:00082177
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.5507/bp.2014.060
UT WoS 000359128900007
Keywords in English metabolic syndrome; schizophrenia; depression; sex/gender differences; adipokines; leptin; adiponectin; resistin; AFABP
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 13/7/2020 10:03.
Abstract
Background. There is a growing interest in metabolic alterations in patients with psychiatric disorders due to their increased risk for metabolic syndrome (MetS) development. Inflammation is known to underlie the pathophysiology of schizophrenia and depression as well as MetS. Vulnerability factors for schizophrenia/depression and MetS hence appear to be shared. Methods and Results. Based on a Web of Science search, this review examines current evidence for MetS pathophysiology involving dysregulation of adipose tissue signaling – adipokines and pro-inflammatory cytokine, both also known to be aberrant in schizophrenia/depression. Further, gender differences in the incidence and course of schizophrenia/depression were reported. The disturbances linked to the MetS are also described. Therefore, this review further maps the gender differences in the psychiatric-metabolic comorbidities. Conclusion. There is evidence supporting a pathological predisposition to MetS in both schizophrenia and depression in both humans and animal models. This predisposition is dramatically enhanced by antipsychotic medication. Further, there are gender differences from clinical findings suggesting women with schizophrenia/depression are more vulnerable to MetS development. This has not yet been assessed in animal studies. We suggest further validation of existing schizophrenia and depression animal models for the assessment of metabolic disturbances to provide tools for developing new antipsychotics and antidepressants with “metabolically inert” profile or improving the metabolic status in schizophrenic/depressed patients.
Links
ED1.1.00/02.0068, research and development projectName: CEITEC - central european institute of technology
MUNI/A/0886/2013, interní kód MUName: Farmakodynamické, farmakokinetické a farmakogenetické přístupy v preklinické fázi výzkumu a vývoje léčiv (Acronym: FDN, FKK a FGEN studie)
Investor: Masaryk University, Category A
PrintDisplayed: 28/4/2024 02:40